News & Updates
Filter by Specialty:
Docetaxel, valrubicin do well as rescue treatment for recurrent NMIBC
Sequential intravesical valrubicin and docetaxel prove to be an effective salvage treatment for patients with recurrent nonmuscle-invasive bladder cancer (NMIBC), a study has shown.
Docetaxel, valrubicin do well as rescue treatment for recurrent NMIBC
24 Oct 2022
Thrice/week on par with twice/week ultrasound therapy for erectile dysfunction
Low-intensity pulsed ultrasound therapy three times per week has comparable therapeutic effects and safety as that of a twice-a-week session for mild-to-moderate erectile dysfunction (ED) in young and healthy men, reports a study.
Thrice/week on par with twice/week ultrasound therapy for erectile dysfunction
22 Oct 2022
Kidney transplant recipients see lower IgG production after COVID-19 jab
Vaccination against COVID-19 seems to be less effective among kidney transplant recipients, according to a recent study. Cessation or reduction of immunosuppressive treatments may help increase the production of immunoglobulin (Ig)G in these patients.
Kidney transplant recipients see lower IgG production after COVID-19 jab
14 Oct 2022
Cefepime/enmetazobactam effective for suspected gram-negative complicated UTI
Patients with complicated urinary tract infection (UTI) or acute pyelonephritis caused by gram-negative pathogens may fare better with cefepime/enmetazobactam than with piperacillin/tazobactam, as the former is associated with a greater likelihood of achieving treatment success, according to the results of a phase III trial.
Cefepime/enmetazobactam effective for suspected gram-negative complicated UTI
11 Oct 2022
ADT suppresses levels of several androgen precursor steroids
In prostate cancer patients, the initiation of androgen deprivation therapy (ADT) lowers the concentrations of 13 circulating steroids, according to a new study.
ADT suppresses levels of several androgen precursor steroids
04 Oct 2022
Secondary kidney stones: to remove or not?
Pre-emptive removal of secondary* kidney stones during surgery to remove primary** stones led to fewer relapses and a similar number of emergency-department (ED) visits related to the surgery compared with leaving the secondary stones in place, a study suggests.
Secondary kidney stones: to remove or not?
30 Sep 2022
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
Apixaban is not inferior to enoxaparin for extended-duration venous thromboembolic event (VTE) prophylaxis (EP) following urologic oncology surgery, reveals a study. In addition, apixaban is associated with fewer major complications and compliance-related adverse events.